What top creators are saying about Rocket Lab USA, Inc.(RKLB)

Fell during broad risk-off selling and reached its lowest level of the year at the time; the discussion emphasizes volatility and long-term execution risks.

Potential demand may benefit from customers seeking alternatives to relying solely on SpaceX and diversifying providers, though customer wins and future performance are uncertain.

Rocket Lab was mentioned as a possible beneficiary when customers seek alternatives to relying on SpaceX or Starlink, preserving supplier choice and negotiating leverage. No company-specific operating update was provided.

Mentioned as rising, without a percentage or specific investment analysis.

Mentioned as a stock an investor regretted not buying earlier. No current investment thesis, valuation view, or recommendation was provided.

The speaker would be interested around $20 but framed it as a high-risk growth investment subject to large drawdowns.

A guest disclosed being an investor, but provided no detailed thesis, valuation view, or risk analysis.

Mentioned retrospectively as a stock that could have produced a better investment outcome in 2024; no current recommendation was provided.

Rocket Lab was mentioned as a high-beta stock that rebounded during the session after recent declines; no company-specific investment analysis was offered.

A speaker regretted not buying Rocket Lab earlier, but gave no current valuation view or buy recommendation.

The acquisition of Iridium could add satellite communications capabilities, but its financial impact was not detailed. A past large share issuance underscores dilution and volatility risks.

Mentioned favorably as a stock that had performed well in 2024, without a current recommendation or company-specific investment thesis.

The guest described herself as an investor and regretted not putting more money into the stock in 2024.

Mentioned mainly in the context of market moves, valuation, or volatility; no current recommendation was provided.

The stock had fallen substantially from prior highs, with delays to the Neutron rocket program weighing on shares; SpaceX's performance does not establish a direct benefit.

Mentioned only in the market-price rundown.

Named as a former Silicon Valley Bank customer for historical context; no company-specific outlook or stock recommendation is provided.

Shares were under pressure amid a delay involving the Neutron rocket. The cited $50 level was notable but was not presented as a price target.

Mentioned in a brief market update without company-specific investment analysis.

Cantor Fitzgerald reiterated an overweight rating, citing launch experience, rocket variety, customer diversification, and dedicated launch pads. Neutron delays and valuation remain risks.

Cited as an example of an unusual investment opportunity that later became a very large business. No current valuation, forecast, or specific recommendation was provided.

The image showed the stock declining amid broad selling pressure.

A delay to the Neutron rocket program was negative, and the host noted the stock traded around 40 times sales. The investment case depends on execution and schedule progress; a recovery to prior levels was not assured.

Briefly quoted in a market snapshot, with no specific investment analysis.

Offers public-market exposure to the launch theme, but the discussion says it remains far behind SpaceX and provides no specific financial outlook. Monitor launch reliability, scale, and customer demand.

The host characterized Rocket Lab as a long-term holding with sustainable earnings potential, but the discussion offered no detailed valuation case or company-specific analysis.

A possible rebound is anticipated; $1,000 was invested.

Another delay to its Neutron rocket program added execution risk and pressure to a stock the host described as highly valued.

Its first Neutron launch has been delayed until 2027. The author is not rushing to open a position, though a quoted post says the stock would become interesting at $45–$55; it was around $55.46 after-hours.

Shares fell about 7–8% after the first Neutron launch was pushed to 2027. The growth case depends heavily on Neutron execution, while the stock was described as expensive at roughly 40 times sales.

Despite the speaker's view that the company was executing strongly, shares fell about 8%, illustrating that broad market sentiment can overshadow company progress.

The speaker expected further downside to be more likely than an immediate reversal and said the stock could remain under pressure for months.

Neutron’s first launch was moved into next year after a manufacturing issue with a propellant dome, creating execution and timing risk; the company said it had addressed the issue and was prioritizing reliability.

The stock was consolidating after a strong move. The guest said a pullback could be worth watching but noted that a breakout was not confirmed.

Was among the high-beta space stocks falling during the session amid competition concerns and uncertain execution timelines.

The author would reconsider the stock at $45–$55 but believes its projected 34.42% sales growth does not currently justify its 25.95x fair-value ratio.

Shares fell about 4% and had been taking hits despite intermittent momentum; competition and shifts in market themes can affect sentiment.

The host expects a short-term decline. A bounce failing below $71 would be weak, while reclaiming $78.25 would improve the outlook.

Rocket Lab was mentioned among growth stocks under pressure, with no specific company development or price target discussed.

Rocket Lab was essentially flat after prior weakness and was noted for its retail-investor following, but no company fundamentals or recommendation were discussed.

The stock was affected by broader high-beta selling, with no additional company-specific investment thesis provided.

The stock was described as consolidating in an accumulation phase. The guest favored monitoring its range and waiting for a move above $85 for stronger confirmation.

The stock rebounded after recent weakness, but the discussion offered no specific company catalyst or investment recommendation.

Rocket Lab fell about 1.4% and did not follow SpaceX higher; the discussion offered no separate fundamental thesis or target.

The stock rose about 5% amid positive momentum in space-related names and discussion of space-based computing and contracts, without a company-specific forecast.

The outlook depends on the Neutron launch program and eventual profitability; the host considered the stock speculative and cited $70–$80 as his fair trading range.

Mentioned in the market scan in connection with short-term market movements, without a substantive investment thesis.

Mentioned in an aerospace and defense market roundup without company-specific analysis or a recommendation.

Mentioned as an example of a company that has pursued acquisitions; the discussion focused on integration rather than its investment outlook.

Mentioned in an intraday market snapshot without a distinct investment thesis or recommendation.